PURPOSE: Several studies have examined the association between diabetes mellitus (DM) and prostate cancer (PCa) risk and progression, however nearly all of these studies have compared diabetic versus non-diabetic men. We sought to investigate the role of glycemic control, as measured by HbA1c, on PCa aggressiveness and prognosis in men with DM and PCa from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. METHODS: We identified 247 men in SEARCH with DM and a recorded HbA1c value within the 12 months prior to radical prostatectomy between 1988 and 2009. We divided these men into tertiles by HbA1c level. The associations between HbA1c tertiles and risk of adverse pathology and biochemical recurrence were tested using multivariate logistic regression and Cox proportional hazards models, respectively. RESULTS: Median HbA1c level was 6.9. On multivariate analysis, HbA1c tertiles were predictive of pathological Gleason score (P-trend = 0.001). Relative to the first tertile, men in the second (OR 4.68, P = 0.003) and third tertile (OR 6.60, P < 0.001) were more likely to have Gleason score > or = 4 + 3. HbA1c tertiles were not associated with margin status, node status, extracapsular extension or seminal vesicle invasion (all P-trend > 0.2). In the multivariate Cox proportional hazards model, increasing HbA1c tertiles were not significantly related to risk of biochemical recurrence (P-trend = 0.56). CONCLUSION: Men with higher HbA1c levels presented with more biologically aggressive prostate tumors at radical prostatectomy. Although risk of recurrence was unrelated to HbA1c levels, further studies are needed to better explore the importance of glycemic control on long-term outcomes in diabetic men with PCa. (c) 2010 Wiley-Liss, Inc.
PURPOSE: Several studies have examined the association between diabetes mellitus (DM) and prostate cancer (PCa) risk and progression, however nearly all of these studies have compared diabetic versus non-diabeticmen. We sought to investigate the role of glycemic control, as measured by HbA1c, on PCa aggressiveness and prognosis in men with DM and PCa from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. METHODS: We identified 247 men in SEARCH with DM and a recorded HbA1c value within the 12 months prior to radical prostatectomy between 1988 and 2009. We divided these men into tertiles by HbA1c level. The associations between HbA1c tertiles and risk of adverse pathology and biochemical recurrence were tested using multivariate logistic regression and Cox proportional hazards models, respectively. RESULTS: Median HbA1c level was 6.9. On multivariate analysis, HbA1c tertiles were predictive of pathological Gleason score (P-trend = 0.001). Relative to the first tertile, men in the second (OR 4.68, P = 0.003) and third tertile (OR 6.60, P < 0.001) were more likely to have Gleason score > or = 4 + 3. HbA1c tertiles were not associated with margin status, node status, extracapsular extension or seminal vesicle invasion (all P-trend > 0.2). In the multivariate Cox proportional hazards model, increasing HbA1c tertiles were not significantly related to risk of biochemical recurrence (P-trend = 0.56). CONCLUSION:Men with higher HbA1c levels presented with more biologically aggressive prostate tumors at radical prostatectomy. Although risk of recurrence was unrelated to HbA1c levels, further studies are needed to better explore the importance of glycemic control on long-term outcomes in diabeticmen with PCa. (c) 2010 Wiley-Liss, Inc.
Authors: Jocelyn S Kasper; Yan Liu; Michael N Pollak; Nader Rifai; Edward Giovannucci Journal: Cancer Causes Control Date: 2008-03-14 Impact factor: 2.506
Authors: Farnoosh Nik-Ahd; Lauren E Howard; Adva T Eisenberg; William J Aronson; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland Journal: Cancer Date: 2019-04-29 Impact factor: 6.860
Authors: M Gacci; G I Russo; C De Nunzio; A Sebastianelli; M Salvi; L Vignozzi; A Tubaro; G Morgia; S Serni Journal: Prostate Cancer Prostatic Dis Date: 2017-02-21 Impact factor: 5.554
Authors: Jeannette M Schenk; Marian L Neuhouser; Sarah J Beatty; Matthew VanDoren; Daniel W Lin; Michael Porter; John L Gore; Roman Gulati; Stephen R Plymate; Jonathan L Wright Journal: Contemp Clin Trials Date: 2019-04-16 Impact factor: 2.226
Authors: J L Wright; S R Plymate; M P Porter; J L Gore; D W Lin; E Hu; S B Zeliadt Journal: Prostate Cancer Prostatic Dis Date: 2013-03-05 Impact factor: 5.554
Authors: R M Joentausta; P M Kujala; T Visakorpi; T L J Tammela; T J Murtola Journal: Prostate Cancer Prostatic Dis Date: 2016-08-09 Impact factor: 5.554
Authors: Ana Belen Sanz; Maria Dolores Sanchez-Niño; Susana Carrasco; Felix Manzarbeitia; Olga Ruiz-Andres; Rafael Selgas; Marta Ruiz-Ortega; Carmen Gonzalez-Enguita; Jesus Egido; Alberto Ortiz Journal: PLoS One Date: 2012-10-15 Impact factor: 3.240